持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2023/12/15 | 日証協 | 173,039株 | -3.49% | 152,646株 | +11.24% | 177,630株 | -0.84% | 7,301株 | -60.29% |
2023/12/08 | 日証協 | 179,288株 | -3.28% | 137,224株 | -0.51% | 179,128株 | -3.87% | 18,386株 | -40.09% |
2023/12/01 | 日証協 | 185,372株 | +8.81% | 137,924株 | -66.25% | 186,343株 | +6.88% | 30,687株 | -5.41% |
2023/11/24 | 日証協 | 170,363株 | -3.61% | 408,614株 | +29.23% | 174,340株 | +0.39% | 32,443株 | +14.9% |
2023/11/17 | 日証協 | 176,748株 | +3.96% | 316,192株 | +38.31% | 173,657株 | -1.02% | 28,236株 | +21.18% |
2023/11/10 | 日証協 | 170,008株 | +2.47% | 228,619株 | -16.09% | 175,439株 | +3.04% | 23,300株 | +30.74% |
2023/11/02 | 日証協 | 165,908株 | +4.67% | 272,449株 | +8.43% | 170,261株 | +5.66% | 17,822株 | -45.09% |
2023/10/27 | 日証協 | 158,508株 | +14.12% | 251,275株 | +55.21% | 161,139株 | -14.5% | 32,458株 | -43.13% |
2023/10/20 | 日証協 | 138,894株 | +0.58% | 161,894株 | +43.86% | 188,466株 | -1.44% | 57,079株 | -41.25% |
2023/10/13 | 日証協 | 138,094株 | +1.83% | 112,533株 | -51.1% | 191,229株 | -2.9% | 97,151株 | -27.06% |
2023/10/06 | 日証協 | 135,607株 | +218.92% | 230,146株 | +120.42% | 196,944株 | +25.08% | 133,190株 | +49.71% |
2023/09/29 | 日証協 | 42,521株 | +50.68% | 104,414株 | +110.2% | 157,451株 | +3.64% | 88,967株 | -3.08% |
2023/09/22 | 日証協 | 28,220株 | +1.42% | 49,674株 | +44.97% | 151,925株 | +4.49% | 91,794株 | +74.65% |
2023/09/15 | 日証協 | 27,824株 | +69.43% | 34,266株 | +1293.49% | 145,391株 | -1.48% | 52,558株 | -11.74% |
2023/09/08 | 日証協 | 16,422株 | -27.2% | 2,459株 | -54.46% | 147,568株 | -3.99% | 59,548株 | -38.53% |
2023/09/01 | 日証協 | 22,559株 | -55.45% | 5,400株 | -94.52% | 153,700株 | -12.93% | 96,867株 | -9.71% |
2023/08/25 | 日証協 | 50,633株 | +15.24% | 98,581株 | +165.09% | 176,517株 | +17.98% | 107,281株 | +133.73% |
2023/08/18 | 日証協 | 43,938株 | +0.87% | 37,188株 | -38.89% | 149,617株 | +2.33% | 45,900株 | -6.89% |
2023/08/10 | 日証協 | 43,558株 | +6.87% | 60,857株 | -3.6% | 146,212株 | +4.35% | 49,295株 | -46.77% |
※株式分割は考慮していませんのでご注意ください。
Page Top